Logo

Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)

Share this
Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)

Celltrion to Initiate P-I trial for CT-P39 (biosimilar- omalizumab)

Shots:

  • Celltrion plans for the onset of P-I trial for CT-P39 referencing Xolair- and further plans to enter P-III trial in H1’20 with its expected commercialization by 2020
  • The P-I trial will involve assessing of CT-P39-EU-licensed Xolair and US-licensed Xolair evaluating PK and safety in 171 patients in with its expected completion in Aug’20. In Dec 2018- Celltrion began to develop CT-P39 and is focused on the US markets accounting for ~70% of the branded drug’s global sales
  • CT-P39 is a mAb targeted for the treatment of allergic asthma and chronic urticaria. According- to IQVIA- the global sales Xolair reached 3.3 trillion won ($2.7 billion) in 2018

Click here to read full press release/ article | Ref: Celltrion | Image: Twitter


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions